Updates in Breast Cancer Management
-
Location
Citadines Hotel, Abha, Asir, Saudi Arabia
-
Phone
+966 0530373337
- Website: No Website Join Event
- Email Address: info@evidence-academics.com
- Email Activity Coordinator: alimahfouz1981@gmail.com
- Phone Activity Coordinator: +966 556823799
Event Audience
Event Goals
- describe the available options for fertility preservation in premenopausal breast cancer patients and assess their suitability for different patient profiles
- compare and contrast different endocrine therapy regimens for high-risk breast cancer patients and determine their optimal use
- evaluate the role of adjuvant systemic therapy in early breast cancer and integrate updated treatment recommendations into their practice
- analyze the benefits and risks associated with SLNB versus ALND and determine the best surgical approach for different patient scenarios
- discussed treatment strategies in their daily oncology practice to enhance patient care.
Event Agenda
07/05/2025
Introduction and Welcoming.
19:00:00 - 19:05:00
Speaker(s):
No speakers assigned
07/05/2025
Fertility preservation in premenopausal women
19:05:00 - 19:25:00
Speaker(s):
ممدوح عبدالمقتدر اسكندر (MAMDOH ABDULMKTADAR ESKANDAR)
07/05/2025
Best Approach in Endocrine Therapy for High-Risk woman in Breast cancer.
19:25:00 - 19:45:00
Speaker(s):
محمد حسن شبيلي (MUHAMMAD HASSAN SHUBAILI)
07/05/2025
Adjuvant Systemic therapy for Early Breast Cancer.
19:45:00 - 20:05:00
Speaker(s):
علي محمد آل حنش (ALI MOHAMMED ALHANASH)
07/05/2025
Updates on Sentinel Lymph Nodes Biopsy (SLNB) Vs Axillary Lymph Node Dissection (ALND) in breast cancer
20:05:00 - 20:45:00
Speaker(s):
عبدالرحمن محمد القحطاني (ABDULRAHMAN MOHAMMED ALQAHTANI)
07/05/2025
Question and Answers.
20:45:00 - 21:30:00
Speaker(s):
عبدالعزيز موسي عسيري (ABDULAZIZ MOSSA ASSERI)
, علي محمد آل حنش (ALI MOHAMMED ALHANASH)
, عبدالرحمن محمد القحطاني (ABDULRAHMAN MOHAMMED ALQAHTANI)
, ممدوح عبدالمقتدر اسكندر (MAMDOH ABDULMKTADAR ESKANDAR)
, محمد حسن شبيلي (MUHAMMAD HASSAN SHUBAILI)
© 2024 Marvel Developed by Marvel Development Team
